{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:40:22Z","timestamp":1777131622017,"version":"3.51.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,5]]},"DOI":"10.1097\/cm9.0000000000000445","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T09:11:41Z","timestamp":1568970701000},"page":"2315-2324","source":"Crossref","is-referenced-by-count":9,"title":["First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China"],"prefix":"10.1097","volume":"132","author":[{"given":"Xue-Ru","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Bo","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Dong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Qiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-Hua","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Lin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R4-7-20210129","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","article-title":"Guideline of prevention and treatment for chronic hepatitis B (2015 update)","volume":"5","author":"Hou","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"R6-7-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"R8-7-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","article-title":"HBsAg loss with Peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2016.05.024","article-title":"Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: a randomized controlled study","volume":"65","author":"Sun","year":"2016","journal-title":"J Hepatol"},{"key":"R10-7-20210129","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"R11-7-20210129","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/cid\/ciu702","article-title":"A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B \u201ce\u201d antigen-positive chronic hepatitis B","volume":"59","author":"Xie","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40261-016-0486-8","article-title":"Cost-effectiveness comparison between the response-guided therapies and monotherapies of nucleos(t)ide analogues for chronic hepatitis B patients in China","volume":"37","author":"Lai","year":"2017","journal-title":"Clin Drug Investig"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.vaccine.2009.06.035","article-title":"WHO Guide for standardisation of economic evaluations of immunization programmes","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2015.12.046","article-title":"Combination therapy with tenofovir and peginterferon may not be translated into current clinical practice","volume":"150","author":"Fan","year":"2016","journal-title":"Gastroenterology"},{"key":"R17-7-20210129","first-page":"S43","article-title":"Efficacy and safety of 240 weeks of treatment with tenofovir disoproxil fumarate for Chinese patients with chronic hepatitis B","volume":"11","author":"Hou","year":"2017","journal-title":"Hepatology International"},{"key":"R18-7-20210129","first-page":"46","article-title":"Study on the natural history of chronic hepatitis B (in Chinese)","volume":"10","author":"Wu","year":"2002","journal-title":"Chin J Hepatol"},{"key":"R19-7-20210129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13291","article-title":"Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)","volume":"37","author":"Grossi","year":"2017","journal-title":"Liver Int"},{"key":"R20-7-20210129","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1440-1746.2005.03813.x","article-title":"Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression","volume":"20","author":"Lin","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B","volume":"49","author":"Chen","year":"2009","journal-title":"Hepatology"},{"key":"R23-7-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12072-007-5001-0","article-title":"Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study","volume":"1","author":"Chen","year":"2007","journal-title":"Hepatol Int"},{"key":"R24-7-20210129","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1046\/j.1440-1746.2003.03187.x","article-title":"Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China","volume":"18","author":"Xu","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"821","DOI":"10.7326\/0003-4819-142-10-200505170-00007","article-title":"Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis","volume":"142","author":"Kanwal","year":"2005","journal-title":"Ann Intern Med"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1245\/s10434-013-3023-5","article-title":"Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome","volume":"20","author":"Wu","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R27-7-20210129","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2036.2008.03691.x","article-title":"Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis","volume":"27","author":"Veenstra","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1016\/j.vaccine.2015.05.082","article-title":"The doses of 10 mug should replace the doses of 5 mug in newborn hepatitis B vaccination in China: a cost-effectiveness analysis","volume":"33","author":"Yin","year":"2015","journal-title":"Vaccine"},{"key":"R30-7-20210129","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/hep.28310","article-title":"Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection","volume":"63","author":"Fan","year":"2016","journal-title":"Hepatology"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000000445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T12:39:49Z","timestamp":1612010389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,5]]},"references-count":24,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000000445","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,5]]}}}